Inhibrxの価格/販売
Inhibrxの価格/販売は何ですか。
Inhibrx, Inc.の価格/販売は691.46です。
価格/販売の定義は何ですか。
価格対売上比率は、収益と比較した会社の株価です。
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
NASDAQのセクタHealth Careにおける価格/販売の企業と比べるInhibrx
Inhibrxは何をしますか。
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrxと類似の価格/販売
- Insilcoの価格/販売は672.80です。
- Uranium Participationの価格/販売は673.57です。
- Kadestone Capitalの価格/販売は679.35です。
- Nuveen Municipal Credit Opportunities Fundの価格/販売は682.87です。
- Great Boulder Resourcesの価格/販売は687.08です。
- Global Atomicの価格/販売は690.39です。
- Inhibrxの価格/販売は691.46です。
- Thin Film Electronics ASAの価格/販売は694.91です。
- BioPharmXの価格/販売は695.03です。
- Petro Matadの価格/販売は698.32です。
- Chesser Resourcesの価格/販売は703.97です。
- Prospect Park Capitalの価格/販売は709.23です。
- Shonghoya Intl Incの価格/販売は712.65です。